Harry S. Porterfield

466 total citations
20 papers, 378 citations indexed

About

Harry S. Porterfield is a scholar working on Immunology and Allergy, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Harry S. Porterfield has authored 20 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology and Allergy, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Harry S. Porterfield's work include Allergic Rhinitis and Sensitization (6 papers), Food Allergy and Anaphylaxis Research (6 papers) and Contact Dermatitis and Allergies (4 papers). Harry S. Porterfield is often cited by papers focused on Allergic Rhinitis and Sensitization (6 papers), Food Allergy and Anaphylaxis Research (6 papers) and Contact Dermatitis and Allergies (4 papers). Harry S. Porterfield collaborates with scholars based in United States and Australia. Harry S. Porterfield's co-authors include Stephen C. Dreskin, Mark W. Duncan, A. Wesley Burks, Kirk C. Hansen, Gary A. Bannon, Ray McDermott, Stefan Böck, Yonghua Zhuang, J. Lew and Michael D. Kulis and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and PEDIATRICS.

In The Last Decade

Harry S. Porterfield

19 papers receiving 371 citations

Peers

Countries citing papers authored by Harry S. Porterfield

Since Specialization

Citations

This map shows the geographic impact of Harry S. Porterfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry S. Porterfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry S. Porterfield more than expected).

Fields of papers citing papers by Harry S. Porterfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry S. Porterfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry S. Porterfield. The network helps show where Harry S. Porterfield may publish in the future.

Co-authorship network of co-authors of Harry S. Porterfield

This figure shows the co-authorship network connecting the top 25 collaborators of Harry S. Porterfield. A scholar is included among the top collaborators of Harry S. Porterfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry S. Porterfield. Harry S. Porterfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative phenotypic and genotypic antimicrobial susceptibility surveillance in Achromobacter spp. through whole genome sequencing 2025 ·Microbiology Spectrum ·(unknown), (unknown), Christopher Scudder, Melissa Ly, Harry S. Porterfield, Richard D. Smith, Andrew E. Clark, Julia Johnson, Sanchita Basu Das	3
2	Multiplexing the Identification of Microorganisms via Tandem Mass Tag Labeling Augmented by Interference Removal through a Novel Modification of the Expectation Maximization Algorithm 2024 ·Journal of the American Society for Mass Spectrometry ·Gelio Alves, Aleksey Y. Ogurtsov, Harry S. Porterfield, Tapan K. Maity, Lisa M. Jenkins, David B. Sacks, Yi‐Kuo Yu	2
3	Parallel evolution of linezolid-resistant Staphylococcus aureus in patients with cystic fibrosis 2023 ·Microbiology Spectrum ·(unknown), (unknown), Nicholas C. Bolden, (unknown), (unknown), L. Boyken, (unknown), (unknown), Andrew L. Thurman, Valérie Reeb, Harry S. Porterfield, Ahmed M. Moustafa, Paul J. Planet, Anthony J. Fischer	2
4	Urine Trouble: Reducing Midstream Clean Catch Urine Contamination Among Children 3–17 Years Old 2021 ·PEDIATRICS ·(unknown), (unknown), M. Bridget Zimmerman, (unknown), Harry S. Porterfield, Stephanie A. Stewart, Matthew A. Rysavy	0
5	418: Linezolid-resistant Staphylococcus aureus in patients with cystic fibrosis 2021 ·Journal of Cystic Fibrosis ·(unknown), (unknown), Ahmed M. Moustafa, Paul J. Planet, Andrea R. Thurman, Alejandro A. Pezzulo, Harry S. Porterfield, Valérie Reeb, Alain Fischer	1
6	MRSA strains with distinct accessory genes predominate at different ages in cystic fibrosis 2021 ·Pediatric Pulmonology ·Harry S. Porterfield, (unknown), (unknown), Andrew L. Thurman, (unknown), (unknown), (unknown), (unknown), L. Boyken, (unknown), Alejandro A. Pezzulo, Sachinkumar B. Singh, (unknown), Bradley Ford, Daniel J. Diekema, Valérie Reeb, Anthony J. Fischer	6
7	Staphylococcus Aureus Genome Sequencing Reveals Strains Associated with Persistence and Poor Outcome in CF 2020 ·Anne Fischer, Harry S. Porterfield, (unknown), (unknown), (unknown), Andrew L. Thurman, (unknown)	1
8	Prevalence and cervical organism burden among Louisiana women with Trichomonas vaginalis infections 2019 ·PLoS ONE ·(unknown), Harry S. Porterfield, (unknown), (unknown), Barbara Van Der Pol, Alison J. Quayle, Chris L. McGowin	4
9	Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor 2019 ·Pediatric Pulmonology ·Sachinkumar B. Singh, (unknown), (unknown), (unknown), Christopher P. Fox, (unknown), (unknown), Harry S. Porterfield, Anthony J. Fischer	31
10	Interstitial duplication of 8q22.1‐q23.1‐ A case report and review of the literature 2019 ·SHILAP Revista de lepidopterología ·Steven Leary, Harry S. Porterfield, (unknown), Benjamin W. Darbro, (unknown)	1
11	Pathology Image of the Month: Mitral Stenosis at Autopsy. 2017 ·PubMed ·Harry S. Porterfield, (unknown), William P. Newman, Robin McGoey	1
12	The 2S albumin allergens of Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of anaphylaxis and can effectively desensitize peanut‐allergic mice 2012 ·Clinical & Experimental Allergy ·Michael D. Kulis, (unknown), J. Lew, (unknown), (unknown), Yonghua Zhuang, (unknown), Mark W. Duncan, Harry S. Porterfield, A. Wesley Burks, Stephen C. Dreskin	66
13	Effector activity of peanut allergens: a critical role for Ara h 2, Ara h 6, and their variants 2009 ·Clinical & Experimental Allergy ·Harry S. Porterfield, (unknown), (unknown), (unknown), Kirk C. Hansen, Mark W. Duncan, Stephen C. Dreskin	88
14	Contribution of Ara h 2 to peanut‐specific, immunoglobulin E‐mediated, cell activation 2007 ·Clinical & Experimental Allergy ·(unknown), Harry S. Porterfield, Rabab El Mezayen, A. Wesley Burks, L. Pons, (unknown), Benjamin Solomon, Jasmina S. Redzic, Ronald J. Harbeck, Mark W. Duncan, Kirk C. Hansen, Stephen C. Dreskin	45
15	The Majority of the Effector Activity of a Crude Peanut Extract Co-purifies with Ara h 2 but not Ara h 1 or Ara h 3 2007 ·Journal of Allergy and Clinical Immunology ·Harry S. Porterfield, Mark W. Duncan, Kirk C. Hansen, Stephen C. Dreskin	2
16	Crude peanut extracts depleted of Ara h 2 retain the ability to cross-link IgE from allergic subjects 2005 ·Journal of Allergy and Clinical Immunology ·(unknown), Harry S. Porterfield, Stephen C. Dreskin	1
17	Comparative potency of Ara h 1 and Ara h 2 in immunochemical and functional assays of allergenicity 2005 ·Clinical Immunology ·(unknown), (unknown), A. Wesley Burks, Gary A. Bannon, Stefan Böck, Harry S. Porterfield, Ray McDermott, Stephen C. Dreskin	93
18	UsToo PC-SPES surveys: review of studies and update of previous survey results. 2000 ·PubMed ·Harry S. Porterfield	16
19	Overview consensus statement. Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer. 2000 ·PubMed ·(unknown), (unknown), David G. Bostwick, F. Debruyne, Jean L. Fourcroy, (unknown), Harry S. Porterfield, Gerald Sufrin, (unknown), Carol S. Hart	2
20	Survey of UsToo Members and Other Prostate Cancer Patients to Evaluate the Efficacy and Safety of PC-SPES. 1999 ·PubMed ·Harry S. Porterfield	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact